Links

Homepage

Stock List

Search by Ticker

News

Login

Genetic Technologies Ltd (NasdaqCM:GENE)
Stock Analysis

GENE1.14
▲ 0.88%0.01

Stock Analysis

The following stock analysis is based on 9.8 years of data (i.e. since Feb 19, 2013). All the stock history has been downloaded.

Stock Exchange

Genetic Technologies Ltd trades on the NasdaqCM exchange in USD dollars.

Sector

It is in the healthcare sector.

Current Status of Genetic Technologies Ltd

It is currently trading at $1.14 ($1.13 the previous day).

Financials

The next reporting date is in -19335 days (1970 01 01).

The current Canada / US exchange rate is 1.35882.



Will This Trend Continue?

The year over year average increase is 5.0% per year assuming steady exponential growth. The actual 5 year average is 41.24. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year1.6038565217391-59.1- Below Average
2 year3.923831944444427.9- Below Average
3 year3.0690602409639240.8+ Above Average
4 year0.90050852713178-25.8- Below Average
5 year1.214007633587822.4- Below Average
Genetic Technologies Ltd is projected by analysts to get to $25.65 within the next 12 months (2150%), but preticted targets range from as high as $25.65 (2150%) and as low as $25(2093%).

Risk

The worst drop it has had in recent years is -99.2%. It has a dropping shape to the stock curve, which means the stock has to be watched closely. If the financials are good, it could be very profitable, however if not it may not recover and should be sold.

Stock shape test

DAYS AG0PRICE
101.195DROPPING
301.195RISING
601.1679RISING
1501.36DROPPING
3652.06DROPPING
8003.83DROPPING
12001.66RISING
16001.32RISING
20000.79RISING


With an average increase of 5.0% year over year, if Genetic Technologies Ltd is bought at the worst time, Stockmarketizer analysts estimate it will take 238.1 months before the stock will recover to the original purchase price.

Tradingview BuySell Widget

Yahoo News Feed

GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetes

Tue, 06 Dec 2022 13:00:00 MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is delighted to announce the publication of a peer-reviewed paper describing the ...... Read Full Article

Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious disease

Thu, 10 Nov 2022 13:00:00 MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies (ASX:GTG, NASDAQ:GENE), a global leader in guideline driven Genomics based tests in health, wellness and serious disease will be hosting an interview between Dr Erika Spaeth (PhD Director of Clinical ...... Read Full Article

Genetype for Ovarian Cancer Published in Prestigious European Journal of Cancer Prevention

Wed, 09 Nov 2022 13:00:00 MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is delighted to announce the publication of a validation study evaluating ...... Read Full Article

Genetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar Details

Tue, 25 Oct 2022 13:14:00 MELBOURNE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based tests in health, wellness and serious disease has released its results for the quarter ended September 30, 2022 (Q1 FY23). Q1 ...... Read Full Article

Genetic Technologies Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Thu, 13 Oct 2022 12:00:00 RedChip Companies will air a new interview with Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) ("Company", "GTG"), a global leader in genomics-based tests in health, wellness, and serious disease, on The RedChip Money Report® on Bloomberg TV, this Saturday, October 15, ...... Read Full Article

Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer

Thu, 29 Sep 2022 12:00:00 MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the recent publication of a paper in the Journal ...... Read Full Article

Genetic Technologies Provides Update on US Operations and Payer Engagement

Fri, 02 Sep 2022 12:00:00 MELBOURNE, Australia, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”, “GENE”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease, is pleased to report excellent commercial progress in the USA ...... Read Full Article

GENE Momentum building - a year in review

Tue, 30 Aug 2022 12:00:00 MELBOURNE, Australia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to report annual results for the year ended June 30, 2022. ...... Read Full Article

Gene achieves key milestones and growth

Thu, 28 Jul 2022 12:00:00 MELBOURNE, Australia, July 28, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease provides its cashflow results for the quarter ended June 30, 2022 (Q4 FY22). Financial Highlights: ...... Read Full Article

GeneType launches Multi-Test in Obstetrics clinics with more than 1,000 referring primary care physicians

Mon, 18 Jul 2022 12:00:00 MELBOURNE, Australia, July 18, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that we are partnering with Melbourne based Siles Health, ...... Read Full Article

Completion of AffinityDNA Acquisition expanding global direct-to-consumer business

Thu, 14 Jul 2022 12:00:00 MELBOURNE, Australia, July 14, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that it has completed the acquisition of the direct-to-consumer ...... Read Full Article

EasyDNA expands Indian and European markets; launching NIPT, Carrier testing and DNA storage

Tue, 05 Jul 2022 12:00:00 MELBOURNE, Australia, July 05, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the Company’s recently acquired, EasyDNA, has embarked on ...... Read Full Article

GeneType Risk Assessment Test onboarding in 16 clinics

Fri, 01 Jul 2022 12:00:00 MELBOURNE, Australia, July 01, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the Company has commenced initial implementation of its geneType ...... Read Full Article

Transformational Pathway to US Payer System; Attributing US$1.4 Billion Health and Economic Benefit from geneType Breast Cancer Risk Assessment Test

Thu, 16 Jun 2022 12:00:00 MELBOURNE, Australia, June 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the completion of an independently developed and validated customizable ...... Read Full Article

Acquisition of global direct to consumer ecommerce business

Mon, 16 May 2022 13:00:00 MELBOURNE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease advises that it has entered into an agreement to acquire the direct-to-consumer eCommerce ...... Read Full Article

Genetic Technologies drives leadership in precision medicine with Multi-Risk Test

Fri, 08 Apr 2022 12:00:00 MELBOURNE, Australia, April 08, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) (“GENE” or the “Company”), a global leader in genomics-based tests in health, wellness and serious disease provides its year to date results for the nine months ended ...... Read Full Article

US Patent Office Grants Patent for COVID-19 Risk Test

Wed, 23 Feb 2022 13:00:00 MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce the granting of US Patent No: US 11,257,569, Methods of ...... Read Full Article

GeneType Multi-Test Receives Regulatory Approval for Commercial Release in USA and Australia

Tue, 22 Feb 2022 13:00:00 MELBOURNE, Australia, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that on February 17, 2022 the Company’s laboratory in Fitzroy, ...... Read Full Article

Genetic Technologies Reports Q2 FY22 Cash Flow Results

Wed, 19 Jan 2022 14:00:00 Q2 momentum sets the stage for a strong FY22MELBOURNE, Australia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ‘Company’, ‘GENE’, ‘geneType’), a diversified Genomics and AI driven preventative health business, provides its results for the quarter ...... Read Full Article

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ‘Company’, ‘GENE’, ‘geneType’), a global leader in genomics-based tests in health, wellness and serious disease provides the following business update:

Tue, 21 Dec 2021 13:00:00 Cash Receipts (A$'000) Cash Receipts (A$'000) Forecast 2QFY221 cash receipts +112% versus the prior quarter (1QFY22) to A$1.8 million following the completed integration of EasyDNA in the quarterMulti-Test technical validation complete and submitted to NATA2 and CMS3 for final ...... Read Full Article
<